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Purpose: To describe serum vascular endothelial growth factor (sVEGF) in patients with neovascular age-
related macular degeneration (nAMD) receiving anti-VEGF agents and associations between sVEGF and sys-
temic serious adverse events (SSAEs).
Design: Exploratory analyses of a randomized controlled trial that enrolled 610 participants with nAMD and
compared 2 anti-VEGF antibodies, ranibizumab and bevacizumab, and 2 treatment regimens, monthly vs.
discontinuous, with 2 years’ follow-up.
Participants: Adults aged 50þ years with treatment-naïve nAMD and a visual acuity of 25 letters (Snellen
equivalent 20/320) in the affected eye.
Methods: Intravitreal injection of anti-VEGF antibodies.
Main Outcome Measures: sVEGF and occurrence of SSAE, with particular interest in arterio-
thromboembolic events (ATE) and immunologically mediated events (IME).
Results: On average, sVEGF (measured atmonths 0, 1, 11, 12, 23, and 24) decreased from a geometricmean of
168 pg/mL at baseline to 64 pg/mL at month 24. The decrease was greater with bevacizumab than with ranibizumab
andwas dependent on time since last treatment; at month 24 sVEGFwas 11% lower with bevacizumab if treated3
months previously, 51% lower if treated 2 months previously, and 76% lower if treated the previous month,
compared with ranibizumab. The hazard of experiencing an ATE increased with age (hazard ratio [HR] ¼ 2.01; 95%
conﬁdence interval [CI] ¼ 1.32e3.05; P ¼ 0.001) and higher sVEGF (HR ¼ 1.16; 95% CI ¼ 1.03e1.30, per 100 unit
rise in sVEGF; P ¼ 0.013). There was no association between sVEGF and the hazard of an IME (HR ¼ 1.01; 95%
CI ¼ 0.76e1.33; P ¼ 0.942); however, the hazard of an IME was signiﬁcantly increased by treatment with bev-
acizumab compared with ranibizumab (HR¼ 3.53; 95%CI¼ 1.35e9.22; P¼ 0.010). The hazard of an “other SSAE”
(not categorized as ATE or IME) increased with age (HR 1.51, 95% CI 1.14e2.01, P ¼ 0.005) and decreased if an
injection had been administered within the previous month (HR ¼ 0.68; 95% CI ¼ 0.45e1.03; P ¼ 0.069).
Conclusions: The decrease in sVEGF is greater with bevacizumab than with ranibizumab, but this
difference is eliminated when treatment is withheld for 3 months. Higher sVEGF increased the hazard of
an ATE and bevacizumab increases the hazard of an IME compared with ranibizumab. Ophthalmology
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that is synthesized by endothelial cells and a variety of
other cell types. It promotes angiogenesis, maintains the
nonthrombogenic status of the vascular endothelium, is
necessary for neuron survival, supports axonal and arterial
co-patterning in developing brain and skin, and, impor-
tantly, is recognized for its role in the health and physi-
ology of blood vessels.1e3 The recognition that VEGF is a
key mediator of pathologic angiogenesis in many condi-
tions including cancer and neovascular age-related macu-
lar degeneration (nAMD) has resulted in the development118  2017 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inof therapies based on VEGF inhibition (anti-VEGF
drugs).4,5
Antibodies and other biologicals that block the effects of
VEGF are now commonly used in the treatment of nAMD.6,7
In the IVAN clinical trial (alternative treatments to Inhibit
VEGF in Age-related choroidal Neovascularisation trial8e10;
trial registration ISRCTN92166560), 2 anti-VEGF drugs and
2 dosing strategies were compared in patients with nAMD.
The primary purpose of the IVAN trial was to test the non-
inferiority of bevacizumab vs. ranibizumab and discontin-
uous vs. continuous (monthly) dosing.c.
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Figure 1. Participant ﬂow through the IVAN trial. sVEGF ¼ serum vascular endothelial growth factor.
Rogers et al  Serum VEGF Associations with Drug, Dosing, and Systemic SAEsWe expected that there would be egress of the anti-VEGF
drugs from the eye into the systemic circulation. Therefore,
we were interested in studying any potential impact on
circulating VEGF levels and we prespeciﬁed the concen-
tration of serum VEGF (sVEGF) over time as a secondary
outcome. We observed that by month 12 sVEGF was
reduced by more than half with bevacizumab and by a far
smaller amount with ranibizumab. These ﬁndings were re-
ported in brief in a manuscript that described the main
functional and morphologic outcomes.10
The VEGF protein has multiple physiological proper-
ties inﬂuencing vascular endothelial health and blood
ﬂow.1,3 Therefore, after observing the difference in
sVEGF by drug, we hypothesized that the frequency with
which systemic serious adverse events (SSAEs) observed
in the IVAN trial,11 particularly those involving the
cardiovascular system, might be related to sVEGF. We
also hypothesized that repeated exposure of the body to
biological therapies has the potential to induce
immunologic sensitization and thus might be related to
immunologically mediated (noncardiovascular) SSAEs.12Here, we report in detail the sVEGF concentrations in
the IVAN trial; the inﬂuence of the two anti-VEGF
drugs and time since last treatment on sVEGF; and the
relationships between sVEGF and predeﬁned categories
of SSAEs over the period when anti-VEGF drugs were
being administered.Methods
Participants gave written informed consent for collection and
analysis of serum samples in the IVAN trial, which was approved
by a UK NHS Research Ethics Committee (reference: 07/NIR03/
37). IVAN randomized participants to bevacizumab or ranibizu-
mab treatment between March 2008 and October 2010. At month
3, after receiving 3 treatments, participants were assigned randomly
to continuous (monthly dosing) or discontinuous treatment
(administered as needed but mandated as a course of 3 consecutive
monthly treatments when restarting treatment). Participants were
reviewed monthly at 23 clinical sites for up to 2 years. Full details
of the IVAN trial design are shown in Figure 1 and published
elsewhere.8e10119
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Analysis
Whole blood was sampled by venipuncture at six prespeciﬁed time
points (baseline and months 1, 11, 12, 23, and 24). Blood was
transported in vacutainer tubes without additives to a central lab-
oratory, which was masked to randomized allocations and clinical
information. The whole blood samples were processed for
extraction of serum, which was then aliquoted and stored
at 80C. Samples were analyzed within 24 months of storage
using a commercially available quantitative sandwich enzyme-
linked immunosorbent assay (Quantikine Human VEGF immu-
noassay; DY 293 B, R&D Systems Inc, Minneapolis, MN). The
determinations were processed according to the manufacturer’s
speciﬁcations. The primary antibody (biotinylated afﬁnity puriﬁed)
is a human VEGF 165 antibody that recognizes VEGF165,
VEGF121, and VEGF165b and does not cross-react with phospha-
tidylinositol glycan anchor biosynthesis class F (PIGF); VEGF-B,
C, or D; or the VEGF receptor ligands VEGF-R1 or R2 below
concentrations of 50 ng/mL. The assay detects unbound VEGF.
The standard curves and samples were analyzed in duplicate. The
samples were not diluted so as to be within the range of the
standard curves, which ranged from 32 to 2000 pg/mL of sVEGF.
Internal controls (blank zero, low control 50 pg/mL and high
control 1000 pg/mL) were included on each plate and values with a
variance >10% were repeated and the unreliable measure dis-
carded. The coefﬁcient of variation was below 20% for the inter-
assay and below 10% for the intra-assay measurements.Classiﬁcation of Systemic Serious Adverse
Events
In the IVAN trial, all SSAEs and deaths were recorded and coded
with the Medical Dictionary for Regulatory Activities (MedDRA
version 14.1). The assignment of the SSAE to the appropriate
MedDRA coding was performed by medically qualiﬁed members
of the IVAN team (UC, SD, and AJL) and discrepant classiﬁca-
tions reviewed by all 3 clinicians and an agreed assignment
reached.
We identiﬁed arteriothromboembolic events (ATE) and
immunologically mediated events (IME). ATE includes those
deﬁned by the Anti-Platelet Trialists’ Collaboration (APTC)13
(myocardial infarction, stroke, deep vein thrombosis [DVT],
pulmonary embolism (PE), hospital admission for angina or
nonocular hemorrhage, transient ischemic attack, and vascular
deaths) and heart failure. Inclusion of heart failure as an ATE
was prespeciﬁed because this is an important cardiac event not
captured by the ATE deﬁnition above.14
Anti-VEGF treatments are biomolecules with the potential to
evoke immunologic responses, giving rise to our hypothesis about
immunologic sensitization being linked to SSAEs. To investigate this
hypothesis, all SSAEsnot classiﬁed asATEswere reviewed and those
considered to be IME (for onset of or ﬂare-up of arthritis, pneumo-
nitis, Bell’s palsy, etc) were identiﬁed (Supplemental Table 1,
available at www.ophthalmologyretina.org). This categorization
was performed by two of the authors (UC and ADD, the latter
having extensive experience of managing patients with immune
disorders).
All other SSAEs were placed in a third category, designated
OTH (signifying other SSAEs not categorized as ATE or IME).
Any discrepant classiﬁcations were reviewed by the 2 clinicians
(UC and ADD) and the ﬁnal assignment of the SSAE category
agreed.
All classiﬁcations were performed with all of the clinicians
masked to treatment allocation.120Statistical Analysis
When sVEGF levels were below the detection limit (32 pg/mL) of
the assay, we uniformly imputed values between 0 and 32 pg/
mL.15 The distributions of sVEGF levels were skewed and,
therefore, are summarized in natural units as geometric means, as
well as means and standard deviations on the loge scale. Cohen’s
d standardized mean differences16 (calculated on the loge scale)
were used to compare baseline sVEGF by age, gender, history of
prior ATEs, smoking status, and diabetes.
Mixed-effects linear regression was used to investigate the
effect of drug and treatment frequency on sVEGF levels over time
(i.e., at baseline and months 12 and 24; if sVEGF data were
missing at months 12 or 24, data from months 11 or 23 were used,
respectively). The model accounted for the correlation between
repeated measurements on the same participant and included time
since last injection (1, 2, or 3þ months) to reﬂect the treatment
received in the months before the sVEGF concentration was
measured (some participants missed visits, so allocation to the
continuous monthly regimen did not ensure that treatment was
received in the previous month). Baseline values were modeled
with the later outcome values to avoid excluding or imputing cases
with missing baseline values. As the sVEGF distribution was
skewed, log transformed values of sVEGF were modeled, and
effect estimates are shown in the ﬁgures as geometric mean ratios
(GMRs) with corresponding 95% conﬁdence intervals (CIs).
To examine the effects of sVEGF, age, gender, drug, and recent
treatment (deﬁned as whether or not an injection was received
during the previous month) on the occurrence of SSAEs, we
analyzed time to ﬁrst occurrence of each SSAE using Cox
regression models (time to ﬁrst ATE, IME, and OTH were inves-
tigated in separate models). This method of analysis allowed in-
formation about treatment (or not) in the preceding month to be
updated monthly; likewise, the sVEGF level was also updated in
the model when new data were available (months 1, 11, 12, and
23). All participants were included in all 3 analyses; if participants
did not experience the event of interest, they were censored at the
time of their ﬁnal visit. Effect estimates are reported as hazard
ratios (HRs) with 95% CIs.
All analyses were performed using Stata 13.1 (StataCorp LP,
College Station, TX).Results
We randomized 628 participants to ranibizumab or bevacizumab,
of whom 610 received the study drugs and formed the analysis
population.8,9 Serum VEGF levels were not available for all par-
ticipants at each of the prespeciﬁed time points for diverse reasons
(participant did not attend; taking the sample was overlooked by
the study site research team; sample deteriorated in transit;
participant had died or withdrawn). The numbers of participants
with samples at each time point are described in the ﬁgures and
tables; all exceeded 75%.
Baseline Associations of Serum Vascular
Endothelial Growth Factor with Demographics
and Clinical History
Average baseline sVEGF levels did not differ by age, smoking
status, history of heart failure, or diabetes (Table 1; standardized
mean differences <0.1). Average sVEGF was higher in women
than in men (Cohen’s d ¼ 0.16) and in participants who had a
history of DVT or PE compared with those who did not
Table 1. Baseline Serum Vascular Endothelial Growth Factor by Demographics and Clinical History
n/N Geometric Mean Mean (SD) loge(sVEGF)
Standardized Mean
Differences* (Cohen’s d)
Age 0.09
50e74 years 194/581 160 5.07 (0.85)
75þ years 387/581 172 5.15 (0.83)
Gender 0.16
Male 235/581 155 5.05 (0.91)
Female 346/581 177 5.18 (0.78)
Smoking status <0.001
Ever smoked 366/575 168 5.12 (0.87)
Never smoked 209/575 168 5.12 (0.76)
History of heart failure 0.06
Yes 113/579 176 5.17 (0.77)
No 466/579 167 5.12 (0.85)
History of myocardial infarction 0.23
Yes 45/581 141 4.95 (0.99)
No 536/581 170 5.14 (0.82)
History of TIA or stroke 0.20
Yes 40/552 143 4.96 (0.97)
No 512/552 169 5.13 (0.83)
History of DVT or PE 0.34
Yes 31/580 220 5.39 (0.89)
No 549/580 166 5.11 (0.83)
Diabetes 0.04
Yes 59/580 163 5.09 (0.89)
No 521/580 169 5.13 (0.83)
DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism; SD ¼ standard deviation; sVEGF ¼ serum vascular endothelial growth factor; TIA ¼ transient
ischemic attack.
*Calculated on the loge scale.
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participants who had a history of myocardial infarction (Cohen’s
d ¼ 0.23) or transient ischemic attack or stroke (Cohen’s
d ¼ 0.20) compared with those who did not.Associations between Serum Vascular
Endothelial Growth Factor and Drug and Dosing
Regimens
Figure 2 (eTable 2, available at www.ophthalmologyretina.org)
shows average sVEGF levels over time, by drug and dosing
regimen. At the baseline visit, the proportion of samples in
which sVEGF could not be detected ranged from 2.0% to
5.6% and the average sVEGF was similar for the 4
randomized groups (geometric mean 154, 164, 173, 182 pg/mL
for continuous and discontinuous ranibizumab and continuous
and discontinuous bevacizumab, respectively). sVEGF reduced
immediately and dramatically when participants were treated
with bevacizumab but more gradually and to a much smaller
extent with ranibizumab.
sVEGF was markedly inﬂuenced by the time that had elapsed
since the last anti-VEGF injection. At both months 12 and 24, the
sVEGF levels were similar for the two drugs for participants who
received their last treatment three or more months previously.
However, sVEGF levels were signiﬁcantly lower in the bev-
acizumab group for participants treated two months (39% lower at
12 months; 51% lower at 24 months) or one month (70% lower at
12 months; 76% lower at 24 months; Figure 3) previously.
sVEGF also appeared to continue to decline with cumulativeexposure to anti-VEGF; by month 12, sVEGF had reduced by
17% (GMR ¼ 0.83; 95% CI ¼ 0.68e1.03; P ¼ 0.089) relative to
the baseline with ranibizumab compared with 75% (GMR ¼ 0.25;
95% CI ¼ 0.19e0.32; P < 0.001) with bevacizumab; sVEGF
continued to fall between months 12 and 24, by a further 13% on
average with ranibizumab and by 31% with bevacizumab
(eFigure 1, available at www.ophthalmologyretina.org). A similar
pattern was observed with the number of injections received; with
bevacizumab, the average sVEGF was notably higher for those
that had up to 4 injections in the ﬁrst year and up to 6
injections over 2 years compared with those that had more
injections; with ranibizumab the pattern was similar but less
marked (eTable 3, available at www.ophthalmologyretina.org).
Associations between Serum Vascular
Endothelial Growth Factor Levels and
Categories of Systemic Serious Adverse Event
Of the 610 participants, 161 (36%) experienced at least 1 SSAE
during their time in the trial. Figure 4 shows the numbers of
participants with the different categories of SSAE; 53
participants had an ATE, 25 had an IME event, and 104 had an
OTH event, with 20 participants experiencing more than 1
SSAE type. Average sVEGF levels in participants at
baseline and at months 1, 11, 12, 23, and 24, classiﬁed by
SSAE type, are described in eTable 4, available at
www.ophthalmologyretina.org.
The Cox regression of time to an ATE event (Figure 5A)
showed that the hazard of experiencing an ATE increased with121
Figure 2. Mean  1 SD loge(sVEGF) over time by treatment arm (SD ¼ standard deviation; sVEGF ¼ serum vascular endothelial growth factor).
Corresponding geometric mean values can be found in eTable 2 (available at www.ophthalmologyretina.org). SDs on the loge scale can be added or
subtracted from the mean on the loge scale and exponentiated to calculate the approximate range within which 68% (1 SD) or 95% (2 SD) of the
data points lie.
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95% CI ¼ 1.03e1.30; P ¼ 0.013) and age (HR ¼ 2.01 per decade;
95% CI ¼ 1.32e3.05; P ¼ 0.001). There was no statistically
signiﬁcant association with drug type.
The analysis of time to an IME event (Figure 5B) found very
different associations; there was no evidence of a statistically
signiﬁcant association between sVEGF levels and hazard of an
IME, but participants receiving bevacizumab were more likely toFigure 3. Differences in serum vascular endothelial growth factor (sVEGF) leve
summary values can be found in eTable 3 (available at www.ophthalmologyret
122experience an IME than those receiving ranibizumab
(HR ¼ 3.53; 95% CI ¼ 1.35e9.22; P ¼ 0.010).
The analysis for OTH SSAEs showed an increased hazard
with increasing age (HR ¼ 1.51 per decade; 95% CI ¼
1.14e2.01; P ¼ 0.004) and a reduced hazard, of borderline
statistical signiﬁcance, with recent treatment (HR ¼ 0.68; 95%
CI ¼ 0.45e1.03; P ¼ 0.069). sVEGF had no effect on the hazard
of an OTH SSAE (Figure 5C).ls between drugs at 12 and 24 months by time since last treatment. sVEGF
ina.org). GMR ¼ geometric mean ratio.
Figure 4. Classiﬁcation of 610 participants into groups according to their experience of systemic serious adverse events (SSAEs). All patients are
included in all SSAE analyses; in the ATE analysis, for example, patients who experience an ATE are coded as having the event and all other patients
(including those who have an IME or OTH event) are censored at their last time of contact. APTC ¼ Anti-Platelet Trialists Collaboration; ATE ¼
arteriothromboembolic event; IME ¼ immunologically mediated event; OTH ¼ other event not ATE or IME; VEGF ¼ vascular endothelial growth
factor.
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In this report, we have examined the relationships between
baseline sVEGF levels and participant characteristics,
characterized changes in sVEGF over a 2-year period, and
investigated the relationship between sVEGF and SSAEs
among participants in the IVAN clinical trial.
The ﬁndings of marginally higher sVEGF level in female
subjects and the positive association between systemic
VEGF and DVT/PE are similar to those previously reported
in the literature.17,18 The association between increased
sVEGF and past history of DVT/PE contrasts with other
literature about systemic administration of anti VEGF agents
and ATEs in patients with cancer, which found that anti-
VEGF agents (reducing circulating VEGF) were associ-
ated with ATEs. This context, in which large doses of the
drugs were administered systemically to patients with severe
life-threatening disease, differs markedly from the one we
report, i.e., treatment of patients expected to have a
reasonable life expectancy in line with their age (the stan-
dardized mortality rate for IVAN participants was substan-
tially less than 1 in the ﬁrst year of the trial) with very small
intravitreal doses of anti-VEGF agents.
We have shown that sVEGF was reduced to a much
greater extent by bevacizumab than by ranibizumab, that the
reduction was apparent after a single intravitreal injection
(by month 1) but continued over time, and that the reduction
was inﬂuenced markedly by the time-since-last-treatment
for bevacizumab and to a lesser extent for ranibizumab.
The larger reduction in sVEGF with bevacizumab, com-
bined with the association of a history of DVT/PE with
increased baseline sVEGF, is consistent with nonsigniﬁcant
trends in systematic reviews for ATEs to be more frequent
with ranibizumab than bevacizumab. Maguire et al19
recently published a meta-analysis of individual patient
data from 5 such trials and reported an adjusted relative risk
of ATEs for bevacizumab vs ranibizumab of 0.89 (95%CI ¼ 0.62e1.28); the Cochrane aggregate meta-analysis,
without 1 trial included in the individual patient data
meta-analysis but with 2 other trials, found a similar result
(risk ratio ¼ 0.92; 95% CI ¼ 0.62e1.37).11
Several other studies have also described changes in
sVEGF after treatment with bevacizumab.20e23 However,
none has found a statistically signiﬁcant change in sVEGF
levels after ranibizumab therapy. Most of these studies
measured sVEGF at baseline and at 1 month, with 1 study
extending its ﬁndings out to 3 months.20 All were small in
terms of their sample size and so only had adequate
power to detect an association of large magnitude. As
sVEGF can fall by more than 50% of its baseline value
after a single intravitreal injection of bevacizumab, we
contend that this change is easily detected at this time
point even when the sample size of a study is small. By
contrast, the fall in sVEGF after intraocular ranibizumab
treatment is small and not detectable for many months
after treatment has commenced, which may explain the
failure of the other smaller studies to ﬁnd this association.
Another possible explanation may lie in those studies that
measured plasma VEGF (pVEGF), which represents the
nonsequestered fraction and which exists in low levels and
thus may be below the detection limit of the assays.20,23
In one of these studies,20 scrutiny of the graphical plots of
change in pVEGF over time shows a fall after treatment
and recovery with time. However, the variability of the
measurements in pVEGF with overlapping error bars
probably resulted in failure to ﬁnd statistical signiﬁcance.
The marked reduction in sVEGF with bevacizumab and
the smaller reduction with ranibizumab over time obscured a
more complex association with time-since-last-treatment.
The difference in the reduction in sVEGF by drug was not
observed when treatment had been withheld for 3 months or
more, whereas the difference was pronounced when a
participant had received treatment the preceding month. Our
ﬁndings support the view that extraocular egress of both of123
Figure 5. A, Hazard ratios describing associations of participant charac-
teristics and serum vascular endothelial growth factor (sVEGF) with sys-
temic serious adverse event (SSAE) classiﬁcation of arteriothromboembolic
event (ATE). B, Hazard ratios describing associations of participant
characteristics and sVEGF with SSAE classiﬁcation of immunologically
mediated event (IME). C, Hazard ratios describing associations of partici-
pant characteristics and sVEGF with SSAE classiﬁcation of other SSAE,
excluding ATEs and IMEs (OTH).
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124these therapeutic antibodies occurs with subsequent binding
to circulating sVEGF.
To the best of our knowledge, this is the ﬁrst study to
examine the relationships between sVEGF levels and SSAE
in the context of intraocular anti-VEGF therapies. We
observed that increased sVEGF was associated with a higher
hazard of ATEs but found no evidence of an association
between sVEGF and IMEs. However, we observed an un-
expected but statistically signiﬁcant increase in risk of an
IME in persons exposed to bevacizumab compared to
ranibizumab. Although not hypothesized a priori, there is a
plausible mechanism to explain this observation. Bev-
acizumab is a full-length monoclonal antibody to VEGF-A;
it is 3 times as large as ranibizumab (molecular weight of
149 kDa) and the presence of the Fc domain slows clearance
and increases the systemic half-life, which is around 20
days.13 Egress of therapeutic agents from the eye may be
modiﬁed by the presence of the Fc domain as the retinal
pigment epithelium (RPE) expresses Fc and FcRN
receptors with binding and internalization of the agent.24
A single study has reported that intraocularly injected
nanoparticles can sequester within the RPE for up to 4
months.25 However, the data on mechanisms by which
biological agents are cleared from within the vitreous
cavity are sparse, and it is not known for how long the
anti-VEGF agents in current use would be sequestered
within the RPE and what the implications might be for RPE
health and immunosensitization. In an elegant study that
examined the elimination of intraocularly administered
molecules, Kim et al26 show the existence of a speciﬁc
mechanism for transporting and clearing full-length immu-
noglobulin G (IgG) into the circulation via the neonatal Fc
receptor. Furthermore, the neonatal Fc receptors function to
protect IgG from elimination from the bloodstream and
tissue distribution and thus could potentially prolong the
half-life of the molecules.27 Also, the presence of the Fc
component on antibody molecules has the potential to
modulate immune responses and in some instances create
the conditions for immunosensitization.28
Recent treatment appeared to be protective of OTH
events; this ﬁnding is in accord with our original observa-
tion10 that participants allocated to discontinuous treatment
(who were more likely to have had longer intervals
without treatment) had a higher frequency of SSAEs. It is
also in accord with ﬁndings from the Comparison of Age-
related macular degeneration Treatment Trials (CATT), in
which a higher frequency of SSAE in the pro re nata
treatment arm was observed, and when combined with the
IVAN trial in a meta-analysis reached statistical signiﬁ-
cance.8,9 This ﬁnding raises the intriguing possibility that an
intermittent dosing strategy could evoke delayed hypersen-
sitivity reactions to the drugs and, thus, an increase in the
frequency of systemic adverse events.12 An alternative
explanation is that the absence of recent treatment is
simply a proxy for poor health, with some patients who
were not recently treated being nonattenders.
Strengths of the IVAN trial were its substantial size, good
retention over 2 years, a high proportion of participants
Rogers et al  Serum VEGF Associations with Drug, Dosing, and Systemic SAEsproviding longitudinal serum measurements at the speciﬁed
sampling time points, rigorous reporting of adverse events,
and the use of a centralized laboratory that was masked to
treatment allocation.
There are several important limitations to our study,
which are primarily due to the fact that this is an exploratory
analysis of data from the IVAN trial8,9 rather than a study
conducted speciﬁcally for the purpose described here.
Firstly, our study does not have a placebo group, pre-
cluding any comparison of sVEGF or SSAE frequencies with
patients unexposed to an anti-VEGF therapy. Thus continuing
concern about the potential for SSAEs related to sVEGF
suppression in high-risk susceptibility groups is justiﬁed.29,30
Secondly, sVEGF measurements were made only at
speciﬁed time points and not at every visit and, therefore,
the sVEGF values used to predict occurrence of an SSAE
may have been measured several months before the SSAE
occurred. This limitation would tend to have diluted asso-
ciations that may have existed but is very unlikely to have
given rise to spurious associations.
Thirdly, the number of IME events was low, limiting the
power of our analyses; despite this, we observed a signiﬁ-
cant association with the drug received.
Fourthly, a limitation may exist regarding our use of serum
samples.31 It was not possible to obtain plasma samples in the
IVAN trial, as the resources for immediate processing of
whole blood samples were not uniformly available in all the
participating clinical sites, and we recognize that this is an
important potential limitation of the present study. VEGF
protein is sequestered in platelets and other blood cells and
is released during clotting. Consequently, sVEGF
concentrations are heavily dependent on blood counts,
which may act as an important confounder,31 although, for
drug and dosing comparisons, this confounder should have
been distributed similarly by group, owing to
randomization. Despite this limitation, robust differences in
sVEGF were detected in participants receiving intraocular
anti-VEGF therapy. In support of the validity of serum mea-
surements, we note that the Framingham study (which
measured both) found that sVEGF and pVEGFmeasurements
were strongly correlated and elected to report many of the
associations solely on sVEGF.24
Finally, the commercial assay we used detects both
VEGF121 and VEGF165 and only requires a single epitope
for binding, which can be located anywhere in the VEGF
molecule. We therefore think that it is unlikely that masking
of the epitope could have resulted in the marked reductions
in sVEGF levels seen in the present study. Furthermore, the
detectable falls in sVEGF after treatment with either drug,
and the larger decrease with monthly bevacizumab treat-
ment, are consistent with the previously observed differ-
ences in pharmacokinetics of ranibizumab and
bevacizumab.13,32 Recent studies have shown that there are
opposing angiogenic and antiangiogenic VEGF-A isoforms,
and a differential reduction in these would not have been
picked up by the commercial enzyme-linked immunosor-
bent assay that we used, which does not discriminate
between them. Thus it is possible that a relationship between
circulating VEGF isoforms and SSAE could have been
missed.33,34The analyses reported in the present study were intended
at the outset to be exploratory, and for this reason our results
should be considered tentative. We strongly recommend that
other studies of patients being treated with anti-VEGF drugs
attempt to replicate what we have described. The Diabetic
Retinopathy Clinical Research Network has collected blood
samples in trials of intraocularly administered anti-VEGF
drugs and would be ideally placed to do this.35
In summary, IVAN is the ﬁrst study to quantify changes
in sVEGF over a 2-year period, describe the relationships
between dosing interval and sVEGF recovery, and investi-
gate associations between sVEGF and other factors with
SSAEs. The latter investigation has an important limitation,
namely that the sVEGF measurements were taken at ﬁxed
time points that were not necessarily close to when an SSAE
occurred. Our ﬁndings broadly support the view that the
falls in sVEGF that occur after exposure to anti-VEGF drugs
are unlikely to be associated with systemic ill effects. The
possibility that bevacizumab may be associated with an
increased risk for IMEs needs to be replicated.
References
1. Ferrara N. Role of vascular endothelial growth factor in
regulation of physiological angiogenesis. Am J Physiol Cell
Physiol. 2001;280:C1358e1366.
2. Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous
system. Organogenesis. 2010;6:107e114.
3. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of
vascular endothelial growth factors. Cardiovasc Res. 2005;65:
550e563.
4. Kourlas H, Abrams P. Ranibizumab for the treatment of
neovascular age-related macular degeneration: a review. Clin
Ther. 2007;29:1850e1861.
5. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for
cancer: current progress, unresolved questions and future
directions. Angiogenesis. 2014;17:471e494.
6. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and
bevacizumab for treatment of neovascular age-related macular
degeneration: two-year results. Ophthalmology. 2012;119:
1388e1398.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med.
2006;355:1419e1431.
8. Chakravarthy U, Harding SP, Rogers CA, et al. A randomised
controlled trial to assess the clinical effectiveness and cost-
effectiveness of alternative treatments to Inhibit VEGF in
Age-related choroidal Neovascularisation (IVAN). Health
Technol Assess. 2015;19:1e298.
9. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative
treatments to inhibit VEGF in age-related choroidal neo-
vascularisation: 2-year ﬁndings of the IVAN randomised
controlled trial. Lancet. 2013;382:1258e1267.
10. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab
versus bevacizumab to treat neovascular age-related macular
degeneration: one-year ﬁndings from the IVAN randomized
trial. Ophthalmology. 2012;119:1399e1411.
11. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of
bevacizumab versus ranibizumab for neovascular age-related
macular degeneration. Cochrane Database Syst Rev. 2014:
CD011230.
12. Baldo BA. Adverse events to monoclonal antibodies used for
cancer therapy: focus on hypersensitivity responses. Oncoim-
munology. 2013;2:e26333.125
Ophthalmology Retina Volume 2, Number 2, February 201813. Semeraro F, Morescalchi F, Duse S, et al. Pharmacokinetic
and pharmacodynamic properties of anti-VEGF drugs after
intravitreal injection. Curr Drug Metab. 2015;16:572e584.
14. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of cel-
ecoxib on cardiovascular events and blood pressure in two
trials for the prevention of colorectal adenomas. Circulation.
2006;114:1028e1035.
15. Beal SL. Ways to ﬁt a PK model with some data below the
quantiﬁcation limit. J Pharmacokinet Pharmacodyn. 2001;28:
481e504.
16. Austin P. Using the standardized difference to compare the prev-
alence of a binary variable between two groups in observational
research. Commun Stat Simul Comput. 2009;38:1228e1234.
17. Carter JG, Gammons MV, Damodaran G, et al. The carboxyl
terminus of VEGF-A is a potential target for anti-angiogenic
therapy. Angiogenesis. 2015;18:23e30.
18. Kikuchi R, Nakamura K, MacLauchlan S, et al. An anti-
angiogenic isoform of VEGF-A contributes to impaired
vascularization in peripheral artery disease. Nat Med. 2014;20:
1464e1471.
19. Maguire MG, Shaffer J, Ying G, et al. Serious adverse events
with bevacizumab or ranibizumab for age-related macular
degeneration: meta-analysis of individual patient data.
Ophthalmol Retina. 2017;1:375e381.
20. Avery RL, Castellarin AA, Steinle NC, et al. Systemic phar-
macokinetics following intravitreal injections of ranibizumab,
bevacizumab or aﬂibercept in patients with neovascular AMD.
Br J Ophthalmol. 2014;98:1636e1641.
21. Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab for
treatment of age-related macular degeneration: effects on
serum VEGF concentration. Curr Eye Res. 2014;39:518e521.
22. Kong L, Bhatt AR, Demny AB, et al. Pharmacokinetics of
bevacizumab and its effects on serum VEGF and IGF-1 in
infants with retinopathy of prematurity. Invest Ophthalmol Vis
Sci. 2015;56:956e961.
23. Wang X, Sawada T, Sawada O, et al. Serum and plasma
vascular endothelial growth factor concentrations before and
after intravitreal injection of aﬂibercept or ranibizumab for
age-related macular degeneration. Am J Ophthalmol.
2014;158:738e744.e1.12624. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery
targeting the retina and retinal pigment epithelium using pol-
ylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44:
3562e3569.
25. Dithmer M, Hattermann K, Pomarius P, et al. The role of Fc-
receptors in the uptake and transport of therapeutic antibodies
in the retinal pigment epithelium. Exp Eye Res. 2016;145:
187e205.
26. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated
pharmacokinetics of therapeutic IgG in the eye. Mol Vis.
2009;15:2803e2812.
27. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms
of therapeutic monoclonal antibodies. Drug Discov Today.
2006;11:81e88.
28. Karsten CM, Kohl J. The immunoglobulin, IgG Fc receptor
and complement triangle in autoimmune diseases. Immunobi-
ology. 2012;217:1067e1079.
29. Avery RL, Gordon GM. Systemic safety of prolonged monthly
anti-vascular endothelial growth factor therapy for diabetic
macular edema: a systematic review and meta-analysis. JAMA
Ophthalmol. 2016;134:21e29.
30. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular
events associated with rofecoxib: ﬁnal analysis of the
APPROVe trial. Lancet. 2008;372:1756e1764.
31. JelkmannW. Pitfalls in the measurement of circulating vascular
endothelial growth factor. Clin Chem. 2001;47:617e623.
32. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics
of Ranibizumab (rhuFabV2) after a single intravitreal admin-
istration. Invest Ophthalmol Vis Sci. 2005;46:726e733.
33. Lieb W, Safa R, Benjamin EJ, et al. Vascular endothelial
growth factor, its soluble receptor, and hepatocyte growth
factor: clinical and genetic correlates and association with
vascular function. Eur Heart J. 2009;30:1121e1127.
34. Pikula A, Beiser AS, Chen TC, et al. Serum brain-derived
neurotrophic factor and vascular endothelial growth factor
levels are associated with risk of stroke and vascular brain
injury: Framingham Study. Stroke. 2013;44:2768e2775.
35. Wells JA, Glassman AR, Ayala AR, et al. Aﬂibercept, bev-
acizumab, or ranibizumab for diabetic macular edema. N Engl
J Med. 2015;372:1193e1203.Footnotes and Financial DisclosuresOriginally received: February 2, 2017.
Final revision: May 29, 2017.
Accepted: May 30, 2017.
Available online: August 18, 2017. Manuscript no. ORET_2017_69.
1 Clinical Trials and Evaluation Unit, School of Clinical Sciences, Uni-
versity of Bristol, Bristol, United Kingdom.
2 Oxford Eye Hospital, Oxford University Hospitals Foundation Trust,
Oxford, United Kingdom.
3 Clinical and Experimental Sciences, Faculty of Medicine, University of
Southampton, Southampton, United Kingdom.
4 School of Clinical Sciences, University of Bristol, Bristol, United
Kingdom.
5 UCL Institute of Ophthalmology and National Institute for Health
Research (NIHR) Biomedical Research Centre at Moorﬁelds Eye Hospital
and University College London Institute of Ophthalmology, London,
United Kingdom.
6 Centre for Experimental Medicine, Queen’s University, Belfast, United
Kingdom.Financial Disclosure(s):
Funding: The IVAN trial is funded by the UK National Institute for Health
Research Health Technology Assessment (NIHR HTA) Programme (proj-
ect number 07/36/01). The views and opinions expressed are those of the
authors and do not necessarily reﬂect those of the HTA programme, the
NIHR, the UK National Health Service, or the Department of Health.
Conﬂicts of Interest: C.A.R.: Lecture honorarium d Novartis. B.C.R.:
Teaching fee d Janssen-Cilag. S.D.: Lecture honorariad Novartis; her
employing institution has received payments from Novartis. A.J.L.:
Chief investigator d trial investigating treatment of chorioretinopathy;
Is principal investigator d trials sponsored by Novartis, the manufac-
turers of ranibizumab; Advisory boards d Novartis and Bayer.
U.C.: Principal investigator d trials sponsored by Novartis; advisory
boards d Novartis, Bayer, and Roche outside the submitted work;
employing institution has received payments d Novartis, Bayer, Neo-
vista, Oraya, and Alcon.
Author Contributions:
Research design: Rogers, Scott, Reeves, Chakravarthy
Data acquisition and/or research execution: Downes, Lotery, Dick,
Chakravarthy
Data analysis and/or interpretation: Rogers, Scott, Reeves
Rogers et al  Serum VEGF Associations with Drug, Dosing, and Systemic SAEsManuscript preparation: Rogers, Scott, Reeves, Downes, Lotery, Dick,
Chakravarthy
Human Subjects: This study includes human subject/tissues. Participants
gave written informed consent for collection and analysis of serum samples
in the IVAN trial, which was approved by a UK NHS Research Ethics
Committee (reference: 07/NIR03/37).
Abbreviations and Acronyms:
ATE ¼ arteriothromboembolic event; CI ¼ conﬁdence interval;
DVT ¼ deep vein thrombosis; GMR ¼ geometric mean ratio;
HR ¼ hazard ratio; IME ¼ immunologically mediated event;nAMD ¼ neovascular age-related macular degeneration;
pVEGF ¼ plasma vascular endothelial growth factor; RPE ¼ retinal
pigment epithelium; SSAE ¼ systemic serious adverse event;
sVEGF ¼ serum vascular endothelial growth factor; VEGF ¼ vascular
endothelial growth factor.
Correspondence:
Usha Chakravarthy, MBBS, FRCOphth, Centre for Experimental Medicine,
Queen’s University of Belfast, Institute for Clinical Science A, Grosvenor
Road, Belfast, BT12 6BA, UK. E-mail: u.chakravarthy@qub.ac.uk.Pictures & PerspectivesFoveal Chorioretinal Anastomosis Secondary to Macular Focal Photocoagulation in Diabetic Retinopathy
A 68-year-old man with diabetic retinopathy treated by macular focal photocoagulation 3 months earlier was referred to our department
because of visual decline in the left eye. Multicolor imaging (A) and infrared reﬂectance (B) showed atrophic spots involving the fovea
resulting from the photocoagulation treatment. Structural OCT (C) revealed the appearance of a break in the retinal pigment epithelium and
Bruch membrane (star) with a hyperreﬂective lesion connecting the inner retina to the choriocapillaris (arrows) corresponding to an
atrophic foveal spot. This lesion was characterized by detectable ﬂow with OCT angiography (dashed arrows) of superﬁcial and deep
capillary plexuses (D, E), avascular outer retina (F), and choriocapillaris (G) (en face view in top panels, cross-sectional view in bottom
panels). The patient was diagnosed with chorioretinal anastomosis secondary to focal photocoagulation. (Magniﬁed version available at
www.ophthalmologyretina.org.)
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